Role of Erythropoietin in the Treatment of Alzheimer's Disease: the Story So Far

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2024 Jun 7

PMID 38846819

Authors

Pavan Kumar Reddy Kalluru

Sushmitha Bhavanthi

Shambhavi Vashist

Ravikishore Reddy Gopavaram

Mahesh Mamilla

Shriya Sharma

Chethan Raj Gundoji

Sumaja Reddy Goguri

Affiliations

Soon will be listed here.

Abstract

This review aims to explore the potential of erythropoietin, a glycopeptide hormone, as a treatment option for Alzheimer's disease, which is the commonest cause of dementia. Despite years of focus and research, therapeutic options for Alzheimer's disease are not yet completely satisfactory. And as people age, they are likely to develop Alzheimer's Disease, further pressuring the healthcare system. So, it is definite to develop treatment options that meet superior outcomes with minimal negative effects. A comprehensive review of the literature was conducted in PubMed and Google Scholar using a combination of keywords, including Alzheimer's disease, dementia, erythropoietin, and neuroprotection. Search results were assessed for relevance before using the data for this study. The beneficial implications of erythropoietin as a therapeutic option have been explored, along with the side effects and mechanisms of erythropoietin in Alzheimer's disease. Overall, the authors' review indicates that erythropoietin presents a promising avenue for mitigating the progression of Alzheimer's disease, with minimal associated side effects.

References

Vogt N, Kerby R, Dill-McFarland K, Harding S, Merluzzi A, Johnson S . Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017; 7(1):13537. PMC: 5648830. DOI: 10.1038/s41598-017-13601-y. View

Miskowiak K, OSullivan U, Harmer C . Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci. 2007; 27(11):2788-92. PMC: 6672568. DOI: 10.1523/JNEUROSCI.5013-06.2007. View

Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M . Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007; 130(Pt 10):2577-88. DOI: 10.1093/brain/awm203. View

Brines M, Cerami A . Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med. 2008; 264(5):405-32. DOI: 10.1111/j.1365-2796.2008.02024.x. View

Zhang F, Xing J, Liou A, Wang S, Gan Y, Luo Y . Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for Neuroprotection against Ischemic Neuronal Injury. Transl Stroke Res. 2010; 1(2):113-21. PMC: 2888513. DOI: 10.1007/s12975-010-0019-3. View

Pickett J, Theberge D, BROWN W, Schweitzer S, Nissenson A . Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis. 1999; 33(6):1122-30. DOI: 10.1016/S0272-6386(99)70150-2. View

Congdon E, Sigurdsson E . Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018; 14(7):399-415. PMC: 6463489. DOI: 10.1038/s41582-018-0013-z. View

DeKosky S, Scheff S . Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990; 27(5):457-64. DOI: 10.1002/ana.410270502. View

Esmaeili Tazangi P, Shid Moosavi S, Shabani M, Haghani M . Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease. Pharmacol Biochem Behav. 2015; 130:15-21. DOI: 10.1016/j.pbb.2014.12.011. View

10.

Jurado Garcia J, Torres Sanchez E, Olmos Hidalgo D, Alba Conejo E . Erythropoietin pharmacology. Clin Transl Oncol. 2007; 9(11):715-22. DOI: 10.1007/s12094-007-0128-y. View

11.

Parra A, Garcia Rodriguez J . Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. Cent Nerv Syst Agents Med Chem. 2012; 12(1):60-8. DOI: 10.2174/187152412800229143. View

12.

Liu W, Shen Y, Plane J, Pleasure D, Deng W . Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol. 2011; 230(2):227-39. PMC: 3114206. DOI: 10.1016/j.expneurol.2011.04.021. View

13.

Rizzo J, Brouwers M, Hurley P, Seidenfeld J, Arcasoy M, Spivak J . American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116(20):4045-59. DOI: 10.1182/blood-2010-08-300541. View

14.

Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K . Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40(12):e647-56. DOI: 10.1161/STROKEAHA.109.564872. View

15.

Cummings J . Alzheimer's disease. N Engl J Med. 2004; 351(1):56-67. DOI: 10.1056/NEJMra040223. View

16.

Thompson H, McCormick W, Kagan S . Traumatic brain injury in older adults: epidemiology, outcomes, and future implications. J Am Geriatr Soc. 2006; 54(10):1590-5. PMC: 2367127. DOI: 10.1111/j.1532-5415.2006.00894.x. View

17.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

18.

Kumagai R, Koike M, Iwase Y, Ichimiya Y . Erythropoietin preparation drastically improved activities of daily living in a patient with severe dementia. Psychiatry Clin Neurosci. 2018; 72(11):849. DOI: 10.1111/pcn.12777. View

19.

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

20.

Yao X, Wang D, Li H, Shen H, Shu Z, Chen G . Erythropoietin Treatment in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Drug Deliv. 2016; 14(6):853-860. DOI: 10.2174/1567201813666160822104813. View